natgillin/translations-raw huggingface dataset:
wherein RD1, RD4, RD5, RD6, RD9, RD11, RD12, RD13, and RD14 are each independently selected from a substituent group consisting of hydrogen, lower alkyl optionally substituted by substituent group C, lower alkenyl optionally substituted by substituent group C, lower alkynyl optionally substituted by substituent group C, carbocyclic group optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, and heterocycle lower alkyl optionally substituted by substituent group C, 
C(=O)-N(RF3)(RF4), (pri čemu je svaki od RF1, RF2, RF3, i RF4, neovisno odabran iz supstituentske skupine koja se sastoji od sljedećih: vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, niži alkenil prema potrebi supstituiran sa supstituentskom skupinom C, niži alkinil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, i heterociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, i Y je ravni ili razgranati niži alkilen);
As an example only pyramids, needles, bumps, cylinders, elongated ribs are cited. 
Samo kao primjer navode se piramide, igle, izbočine, cilindri i izdužena rebra.
The rotating locking mechanism according to the present invention for allowing the proposed function—in particular, the first and/or second stop 19, 22; the first and/or second locking means—may be located within the valve body of the metered dose valve 2 or outside of the valve body. 
Okretni mehanizam za zabravljivanje prema predloženom izumu, koji omogućuje predloženu funkciju - posebno prvi iili drugi graničnik 19, 22; prvo i/ili drugo sredstvo za zabravljivanje - može se zabraviti unutar tijela ventila za odmjeravanje doze 2 ili izvan tijela ventila.
a hydroxyl group; is selected from the group consisting of: a hydrogen atom, 
(6) - hidroksilna skupina; R* se bira iz skupine koju čine:
A dispenser according to clause 19, wherein said limiting mechanism comprises a resiliently deformable portion for applying pressure on said second ring member for said limiting. 
Dispenzer sukladno zahtjevu 14, naznačen time da se navedeni ograničavajući mehanizam (1506) sastoji od elastično deformabilnog dijela za primjenu pritiska na navedeni drugi prstenasti dio (202), (1510).
a binding domain capable of binding to the four Ig domains having seq ID:436, a cystein-rich domain having seq ID:437 or the beta-chain of a sema domain having seq ID:438 of the extracellular domain of c-MET; 
vežuća domena, koja se može vezati na četiri Ig domene sa SEQ ID:436, cisteinom bogatu domenu sa SEQ ID:437 ili beta-lanac sema domene sa SEQ ID:438 izvanstanične domene c-MET;
Exponentially growing CHO-WBL cells were seeded in McCoy's 5A medium supplemented with 10% fetal-bovine serum, L-glutamine (2 mM), penicillin G (100 units/ml), and streptomycin (100 µg/ml) at approximately 0.5 x 106 cells/25 cm2 flask. 
Stanice CHO-WBL sa eksponencijalnim rastom su zasijane u McCoy's SA podlozi dopunjenoj sa 10% fetusnim goveđim serumom, L-glutaminom (2 mM), penicilinom G (100 jedinica/ml), i streptomicinom (100 ug/ml) u približno 0.5 x 10* stanica /25 em? bočice.
The method of claim 14, wherein the further protecting group consists of a dialkyl-, di(cycloalkyl)-, or di(aralkyl)-formamidinyl group where the monomer is adenosine or guanosine. 
Postupak prema zahtjevu 14, naznačen time, da se spomenuta dodatna zaštitna skupina sastoji od dialkil-, di(cikloalkil)- ili di(aralkil)-formamidinil-skupine gdje monomer je adenozin- ili guanozin-monomer.
detecting the formation of the immunological complex; and 
detektiranja nastajanja imunološkog kompleksa;
A conjugate comprising one or more compound(s) according to claim 1 or 2 covalently linked to a cell binding agent through the linking group of the linker(s). 
Konjugat, naznačen time što sadrži jedan ili više spojeva u skladu s patentnim zahtjevom 1 ili 2, kovalentno vezanih na sredstvo za vezanje na stanicu preko povezujuće skupine jedne ili više spojnice.
the control section detects a TPC command targeting an A-SRS for the radio communication terminal apparatus from the control signal and updates the transmission power value of the A-SRS using the TPC command. The radio communication terminal apparatus according to claim 2, wherein: 
Postupak radio komunikacije sukladno zahtjevu 5, sadržeći primanje kontrolne informacije višeg sloja, naznačeno time da se navedeno upravljanje vrijednosti snage prijenosa A-SRS-a inicira nakon navedenog primanja kontrolne informacije višeg sloja.
A pharmaceutical composition comprising a compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 23, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač.
and G have the same meaning as in formula I; the compound of formula IX is reduced to convert it to the compound of formula XI wherein A3, L1, R1, X1, X2, and n are as defined above; and when L1 is nitro, said nitro group is reduced to an amino group and the amino derivative obtained is reacted with a compound of formula III G-A4b-L0 (III), wherein 
A4 1 G imaju isto značenje kao u formuli I; gdje se spoj formule IX reducira kako bi ga se prevelo u spoj formule XI (XI) gdje su A3, L1, R1, X1, X2 in definirani kao gore; i kada je LI nitro, navedenu nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat reagira sa spojem formule III
In another embodiment of the present invention, the subject is in need of treatment for a disorder Various disorders that the compounds of the invention treat or prevent skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. 
Spoj prema patentnom zahtjevu 10, naznačen time što je poremećaj ili bolest izabrana iz grupe koju čine poremećaji 1 bolesti srca, poremećaji i bolesti skeletnih mišića, kognitivni poremećaji, maligna hipertermija, dijabetes 1 sindrom iznenadne smrti novorođenčeta.
the serine at position 129, 130, and 139 are deleted, and the serine at position 136 is replaced with an alanine, 
serin na položaju 129, 130, i 139 je brisan, i serin na položaju 136 je zamijenjen sa alaninom,
The locator 43 is adjusted to the type of contact to be processed, and locks in via a gear arrangement 44 on the tool head 1 a in the adjusted position. 
Kliješta za zatvaranje (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se lokator (43), nakon podešavanja tipu kontakta kojeg treba obraditi, zabravljuje ozubljenjem (44) u podešeni položaj.
When the constituent material of the tear face reaches its breaking stress, the tear face tears along the relief members. 
Kada materijal od kojega je načinjena ploha koja se trga postigne naprezanje kod kojega puca, ploha koja se trga duž reljefnog elemenata.
The method of anyone of paras 1 to 16, wherein the receptor comprises the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2. 
Postupak prema bilo kojem zahtjevu od 27 do 40, naznačen time, da receptor sadrži sekvencu amino kiseline receptora vezanih G-proteina koja ima najmanje oko 80% identiteta od SEQ ID NO:2.
In the diester form, they have also been shown to be effective in the immunoprecipitation of GSTπ from HL-60 cells in vitro, and to be cytotoxic to HL-60 cells in vitro. 
U obliku diestera, oni su također pokazali da su učinkoviti u imunoprecipitaciji GST m iz HL-60 stanica in vitro, i da mogu biti citotoksični za HL-60 stanice in vitro.
A method of making a genetically modified rodent, comprising modifying a rodent genome to comprise at an endogenous Major Histocompatibility Complex II (MHC II) a gene locus a first nucleotide sequence encoding a chimeric human/rodent MHC II a polypeptide and/or at an endogenous Major Histocompatibility Complex II (MHC II) B gene locus a second nucleotide sequence encoding a chimeric human/rodent MHC II B polypeptide, wherein a human portion of the chimeric human/rodent MHC II a polypeptide comprises human MHC II a1 and a2 extracellular domains and/or a human portion of the chimeric human/rodent MHC II B polypeptide comprises human MHC II B1 and B2 extracellular domains, and wherein the chimeric human/rodent MHC II a and/or MHC II B polypeptides form a functional MHC II complex on a surface of a cell of the rodent. 
Postupak proizvodnje genetski modificiranog glodavca, naznačen time, da obuhvaća modificiranje genoma glodavca u svrhu obuhvaćanja, na endogenom a-gen-lokusu glavnog histokompatibilnog kompleksa II (MHC II), prve nukleotidne sekvence koja kodira kimerni ljudski/glodarski MHC II-a-polipeptid, i/ili na endogenom B-gen-lokusu glavnog histokompatibilnog kompleksa II (MHC II), druge nukleotidne sekvence koja kodira kimerni ljudski/glodarski MHC II-B-polipeptid, pri čemu ljudski dio kimernog ljudskog/glodarskog MHC II-a-polipeptida, sadrži ljudske izvanstanične MHC II-a1 i -a2 domene i/ili ljudski dio kimernog ljudskog/glodarskog MHC II-B-polipeptida, sadrži ljudske izvanstanične MHC II-B1 i -B2 domene, i pritom kimerni ljudski/glodarski MHC II-a- i/ili MHC II-B-polipeptidi, tvore funkcionalni MHC II-kompleks na površini stanice glodavca.
melting the conditioning agents, preferably the occlusive and/or emollient conditioning agents, and/or the surfactants, preferably the emulsifying and/or cleaning surfactants, at a temperature that ranges between 70 and 90°C; more preferably it ranges between 75 and 80°C; 
(i) Topljenje emulgacijskih agenasa, poželjno okluzivnih i/ili emolijentnih emulgacijskih agenasa, i/ili površinski aktivnih materija, poželjno emulgatora i/ili površinski aktivnih materija za čišćenje, na temperaturi u opsegu od 70 do 90"C; poželjnije u opsegu od 75 do 80*C;
eluting the plasma-derived target protein from the chromatographic resin. 
(1i) ispiranje iz kromatografske smole ciljanog proteina koji je izveden iz plazme.
The use according to claim 34, wherein the multiple sclerosis is characterized by relapse. 
Uporaba prema zahtjevu 34, gdje je multipla skleroza naznačena relapsom.
An inserter according to claim 1, characterized in that the first end of the insertion tube (6) comprises two diagonally symmetrical connection slots (20) adapted to receive the connection part (19) of the intrauterine system (1). 
Aplikator za umetanje prema zahtjevu 1, naznačen time što prvi kraj cjevčice za umetanje (6) obuhvaća dva dijagonalno simetrična ležišta za primanje okvira (1a) intrauterinog sustava (1).
In step 120, at least a portion of a plurality of the nucleic acid molecules contained in the biological sample are sequenced. 
Postupak prema zahtjevu 1, naznačen time, da su molekule nukleinske kiseline iz biološkog uzorka obogaćene za sekvence manje od 200 bp.
step b): wherein all residues have the definitions as given in claim 1 and R is C1-C4-alkyl and Met means alkalimetals, alkaline earth metals, aluminium, copper, silicon or tin. 
(Vi) . (9) pri čemu svi ostatci imaju definicije kako je navedeno u zahtjevu 1 i R je C;-Cy-alkil i Met predstavlja alkalijske 5
represents a carboxyl group, a tetrazolyl group, -CONHSO2R5, -CO2R5, or any of the following substituents: with the proviso that when R3 is an alkyl group having 1 to 6 carbon atoms substituted with a hydroxyl group and when R4 is a carboxyl group, then R3 and R4 may optionally be fused to form a lactone ring; 
Å e CO,H uz uvjet da kada R, je alkilna skupina koja ima 1 do 6 ugljikovih atoma supstituiranih s hidroksilnom skupinom i kada R, je karboksilna skupina, tada Rs i R, mogu proizvoljno biti kondenzirani tako da tvore laktonski prsten;
The combination dosage form of claim 1 wherein the opioid analgesic agent is in a modified release formulation. 
Kombinirani oblik doziranja u skladu s patentnim zahtjevom 5, naznačen time, da je opioidni analgetik u formulaciji s modificiranim otpuštanjem.
Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include a-glucosidase inhibitors. a-Glucosidase inhibitors belong to the class of drugs which competitively inhibit digestive enzymes such as a-amylase, maltase, a-dextrinase, sucrase, etc. in the pancreas and or small intestine. 
Prikladna farmaceutska sredstva koja se mogu koristiti zajedno sa spojevima prikazanog izuma uključuju inhibitore a- glukozidaze. Inhibitori a-glukozidaze pripadaju skupini spojeva koji kompetitivno inhibiraju probavne enzime poput a- amilaze, maltaze, a-dekstrinaze, saharaze i slično, u pankreasu ili tankom crijevu.
The hybrid formulation according to claim 1 or 2, characterized in that the methacrylic resin is trimethylpropane trimethylacrylate. 
Hibridna formulacija prema patentnom zahtjevu 1 ili 2, naznačena time, da metakrilna smola jest trimetilpropantrimetil akrilat.
A bulky precipitate is formed. 
Formira se pozamašan talog.
is substituted it may be substituted by fluorine, chlorine, cyano, CONH2, methyl, methoxy or trifluoromethoxy; and when B is substituted it may be substituted by methyl. 
supstituiran, može biti supstituiran s fluorom, klorom, cijano, CONH2, metilom, metoksi ili trifluormetoksi; i kad je B supstituiran, može biti supstituiran s metilom.
A reversible, short-acting P2Y12 inhibitor for use in a method according to any one of claims 4 to 7, wherein the invasive procedure is a coronary artery bypass grafting. 
Reverzibilni, kratko djelujući inhibitor P2Y,» za uporabu u postupku prema bilo kojem od zahtjeva 4 do 7, naznačen time da invazivni postupak je premosnica koronarne arterije.
Furthermore, within the context of the present invention, with respect to the mutual adhesion of the pieces of wood, mixed forms are also possible. 
Nadalje, unutar sadržaja predmetnog izuma, u odnosu na međusobnu adheziju komada od drva, mogući su također i miješani oblici.
After separation of the layers, 3 N NaOH (35 mL) was added to the water layer, which was then extracted with MTBE (180 mL + 100 mL). 
Nakon odvajanja slojeva, 3TVNaOH (35 mL) je dodana u vodeni sloj, koji je zatim ekstrahiran sMTBE (180 mL+ 100 mL).
and wherein said first or said second product stream is a cell culture supernatant. 
te time, da je navedeni prvi ili navedeni drugi proizvodni tok stanična kultura koja je isplivala na površinu.
If the terminal has most recently registered with the first register node, its address is correspondingly stored, associated with the hash value, in the hash table of the second register node. 
- = korisnički podaci vezani uz mrežu ili adresa prvog registarskog čvorišta (CDNR1, DNDRI) se pohranjuju, povezani sa hash vrijednošću, u hash tablici drugog registarskog čvorišta (CDNR2, DNLR1).
The nicotine can be in the form of the free base, pharmaceutically acceptable acid addition salts or oxidation products such as nicotine-1′-N-oxide. 
Nikotin može biti u obliku slobodne baze, farmaceutski prihvatljivih kiselih adicijskih soli ili oksidacijskih proizvoda kao stoje nikotin-1'-N-oksid.
the non-naturally encoded amino acid is para-acetyl-phenylalanine that is optionally linked to a linker, polymer, water soluble polymer, or biologically active molecule. 
ne-prirodno kodirana aminokiselina je para-acetil-fenilalanin koja je po izboru povezana sa veznikom, polimerom, polimerom topivim u vodi, ili biološki aktivnim molekulom.
The anti-sclerostin antibody for use according to any one of claims 1-6, wherein the anti-sclerostin antibody is an immunoglobulin comprising heavy chains and light chains. 
Antisklerostinsko antitijelo za primjenu prema bilo kojem zahtjevu od 1 do 6, naznačeno time, što je antisklerostinsko antitijelo imunoglobulin koji sadrži teške lanca i lake lance.
(a-i) the reaction of a compound of the formula (4), or an activated form or derivative thereof with a compound of the formula (5): under amide forming conditions. 
(a-i)reakciju spoja formule (4), ili aktiviranog oblika ili derivate istog sa spojem formule (5): oO OH (4)
The formulation of paragraph 1 wherein the rVWF comprises the amino acid sequence set out in SEQ ID NO: 3; wherein the buffering agent is citrate and the pH is about 7.3; and wherein the amino acid is glycine at a concentration of about 15 mM. 
Formulacija prema zahtjevu 1, naznačena time da rVWF sadrži amino kiselinsku sekvencu prikazanu kao SEQ ID NO:3; gdje je pufer otopina citrata i pH je oko 7.3; i gdje je amino kiselina glicin u koncentraciji od oko 15 mM u otopini.
at least one compartment of the internal combustion engine that comprises used oil or at least one storage compartment comprising used oil, and 
najmanje jedan odjeljak 2 motora s unutrašnjim izgaranjem 1 koji sadrži rabljeno ulje ili najmanje jedan odjeljak za pohranu koji sadrži rabljeno ulje, i
Example 16 Capsules with crystalline form II of N -benzoyl-staurosporine 
(b) kultiviranje otopine s kristalnim oblikom II od N-benzoil-staurosporina;
Suitable metals include alkali and alkali earth metals, for example lithium, sodium, potassium, calcium and magnesium. 
Postupak sukladno zahtjevu 3, naznačen time, što metal je litij, natrij, kalij, kalcij ili magnezij.
The inside diameter φi is chosen according to the type of winding mandrel on which the core 1 is mounted. 
Unutarnji promjer J; odabire se tako da bude sukladan s tipom vretena za namatanje na koji se ulaže jezgra 1.
The mixture was filtered through Celite, evaporated and the residue dissolved in ethyl acetate (300 ml) washed with water (2×100 ml), saturated sodium bicarbonate solution (2×100 ml) and brine (100 ml) and then passed through a hydrophobic frit and evaporated. 
Smjesu se filtrira kroz Celite, te otpari, a ostatak otopi u etil-acetatu (300 ml), ispere vodom (2 x 100 ml), zasićenom otopinom natrijevog bikarbonata (2 x 100 ml) i slanom vodom (100 ml), propusti kroz hidrofobnu fritu, te otpari.
The coating composition was applied to a steel surface and curing carried out at 300°C for 37 seconds. 
Premaz je nanesen na čeličnu površinu i otvrdnjavanje je provedeno pri 300*C za 37 sekundi.
An isolated antibody or fragment thereof that binds specifically to a Dengue virus serotype 1 envelope (E) protein or fragment thereof, wherein the antibody is a human antibody with neutralizing activity that binds across two E proteins in a virus, wherein the binding across two E proteins comprises binding to DI and the hinge between DI and II on one E protein and DIII of a neighboring E protein. 
Izolirano protutijelo ili njegov fragment koji se specifično veže za protein (E) omotača Denga virusa serotipa 1 ili njegov fragment, naznačeno time da je protutijelo ljudsko protutijelo s neutralizirajućom aktivnošću koje se veže preko dva proteina E u virusu, pri čemu vezivanje preko dva proteina E obuhvaća vezanje za DI i zglob između DI i II na jednom proteinu E i DIII na susjednom proteinu E.
Some embodiments further comprise reacting Compound (O) with bis(pinacolato)diboron in the presence of a palladium catalyst comprising a phosphine ligand to form Compound (Y) 
N n (O) s bis(pinakolato)diborom, u prisutnosti paladijskog katalizatora koji sadrži fosfinski ligand, kako bi se dobilo Spoj (Y)
A pharmaceutical combination for use in the treatment of chronic obstructive pulmonary disease, comprising: a first active comprising the compound as defined in any of Claims 1 to 11 and a second active selected from osmotic agents, ENaC blockers, anti-inflammatory agents, bronchodilatory agents, antihistamine agents, anti-tussive agents, antibiotic agents and DNase drug substances, wherein the first and second actives may be in the same or different pharmaceutical composition. 
Farmaceutska kombinacija, naznačena time, da obuhvaća: prvi djelatni sastojak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 1 do drugi djelatni sastojak odabran od sljedećih: osmotska sredstva, ENaC-blokatori, protuupalna sredstva, bronhodilatorna sredstva, antihistaminska sredstva, antitusivna sredstva, antibiotici i ljekovite DNase-supstance, pri čemu prvi i drugi djelatni sastojci mogu biti u istom ili u drugačijem farmaceutskom sastavu.
Therefore it is always a challenge to find an appropriate herbicide or herbicide mixture which fights a certain group of weeds in a certain crop culture. 
Prema tome, uvijek predstavlja izazov naći odgovarajući herbicid ili herbicidnu smjesu koja djeluje protiv određene grupe korova u određenoj kulturi.
The receiver is configured to receive signals from the transmitter, and to generate commands, in response to such signals, which commands control the operation of the yacht. 
Prijemnik je podešen tako da prima signale iz odašiljača te na takve signale generira odgovarajuće komande, kojima se kontrolira upravljanjem jahte.
In practice, the materials used and the contingent dimensions and forms can be any, according to requirements and to the state of the art. A method for producing a profile (15) made of glass fibers (5A, 5B) to be used for strengthening an excavation wall, said method comprising the steps of: 
HR P20140417T1 PATENTNI ZAHTJEVI Postupak za izradu profila (15) načinjenog od staklenih vlakana (5A,5B) za uporabu u ojačavanju zida iskopavanja, pri čemu spomenuti postupak sadrži korake: impregnacija spomenutih staklenih vlakana (5A,5B) polimerskom smolom;
(a-1) measuring the hearing threshold for the respective frequency band. 
(a-1) mjerenje granice čujnosti za respektivne frekvencijske opsege.
intra prediction module for generating a prediction block using a intra prediction mode of a current block; inverse scanning module for generating a quantization block by inverse scanning quantization coefficient information, wherein a scanning type used for inverse scanning is determined based on the intra prediction mode of the current block; 
modul (240) za intrapredikciju konfiguriran da rekonstruira intrapredikcijski režim i da kreira predikcijski blok tekućeg bloka ili podbloka tekućeg bloka; modul za inverzno skeniranje konfiguriran da konvertira informacije o koeficijentu kvantizacije u dvodimenzionalni kvantizacijski blok;
The organic portions are combined and washed with water (2 x 200 ml). 
Organski dijelovi se sjedine i isperu s vodom (2 x 200 ml).
A is selected from the group consisting of 
A je odabran iz skupine koja se sastoji od
A neutralising antibody according to claim 1 which binds human IL-17A and human IL-17F comprising a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3. 
Humanizirano antitijelo koje vezuje VLQELNVTV (SEQ ID NO:45) pri čemu kada se vezuje za HLA-A2 receptor, spomenuto antitijelo obuhvaća varijabilno područje teškog lanca koji se sastoji od aminokiseline koja je prikazana u SEQ ID NO: 16, i varijabilno područje lakog lanca koji se sastoji iz sekvenci aminokiselina koje su prikazane u SEQ ID NOS: 19 ili 20.
The method of claim 1 wherein C is 3-aminophenyl. 
Spoj za uporabu prema zahtjevu 10 gdje € je 3-aminofenil.
A chimeric molecule comprising an antibody or a fragment thereof according to any one of claims 1 to 12, which is a complex molecule having a plurality of functional domains which collectively provides recognition, binding, anchoring, signalling functions to said molecule, in particular said complex molecule being a chimeric antigen receptor (CAR) comprising: 
Himerna molekula koja sadrži antitijelo ili njen fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 12, koja je složena molekula koja ima više funkcionalnih domena koje zajedno daju funkcije prepoznavanja, vezivanja, pričvršćivanja, prijenosa signala za navedenu molekulu, naročito pri čemu je navedena složena molekula himerni receptor antigena (CAR) koji sadrži:
Compound of the formula (VI) 
Spoj sa formulom (VI)